jump to navigation

Shire Receives EMA Approval of Lexington Factory 03/01/2012

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , ,
add a comment

On February 22nd, MBBP client Shire announced that the European Medicines Agency (EMA) has approved the production of its VPRIV enzyme replacement therapies to be made at Shire’s new factory in Lexington, MA. With the additional capacity of a second EMA approved facility, Shire will have the ability to significantly increase the global supply of VPRIV while also providing the company with more manufacturing flexibility.

Please see Shire’s full press release for more information.

Shire plc Joins National Pharmaceutical Council as Newest Member 08/19/2011

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

On August 3rd, the National Pharmaceutical Council, a health policy research organization, announced MBBP client Shire plc as a new member. Dr. Jeffrey M. Jonas, Senior VP, Specialty Pharmaceuticals R&D, will serve as Shire’s representative on the NPC board of directors. In a recent press release, Dr. Jonas describes Shire’s view on the new membership:

Shire is very supportive of NPC’s focus on evidence-based medicine and on policy research related to comparative effectiveness research, pharmaceutical innovation and the value of medicines. We’re pleased to be a part of this organization and look forward to working with NPC on issues affecting the pharmaceutical industry.

In becoming an NPC member, Shire joins with other companies such as Bristol-Myers Squibb Company, GlaxoSmithKline, Johnson & Johnson, and Merck & Co., Inc.

Please visit Shire for more information or visit the National Pharmaceutical Council to view the full press release.

Shire Receives Honorable Mention in Facility of the Year Awards Program 02/03/2011

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

The Facility of the Year Awards (FOYA) are the premier global awards program sponsored by the International Society for Pharmaceutical Engineering (ISPE). The FOYA are  focused on recognizing the innovation and creativity utilized by manufacturing facilities serving the regulated healthcare industry. MBBP client Shire plc has been awarded an 2011 Honorable Mention for their Project Atlas manufacturing facility in Lexington, Massachusetts.

Shire’s Project Atlas facility was selected for extensive deployment of single-use technologies at commercial scale, and the ability to overcome challenges and make technical adaptations which allowed for the facility to be effectively built faster, with reduced investment and lower utility requirements.

Congratulations Shire!

Shire plc Named to MHT “Tech Citizenship” Honoree List 10/22/2010

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

Shire Human Genetic TherapiesLast week, Mass High Tech announced 23 honorees for the 2010 Tech Citizenship Awards which recognize companies for their charitable work through contributions to non-profit community organizations.  MBBP client Shire plc was named as one of the 23 honorees based on the share of revenue that goes toward monetary contributions for charity, contributions in goods, and volunteer hours.

To read the full article, please visit Mass High Tech.

European Commission Approves Shire’s Gaucher Drug 09/15/2010

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
2 comments

MBBP client Shire Human Genetic Therapies was recently featured in a Boston Business Journal article. Shire’s Gaucher disease treatment VPRIV  was approved by the European Commission, thereby allowing VPRIV to be marketed in thirty European countries. VPRIV approval by the U.S. Food and Drug Administration in March 2010 was fast-tracked due to the shortage of Genzyme Corporation’s Gaucher drug Cerezyme.

For more information, please visit Shire.

Patient Data Shows Safe Switch from Genzyme to Shire Drug 04/08/2010

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

Shire Human Genetic TherapiesDue to the temporary closing of Genzyme’s Allston plant last summer, MBBP client Shire’s new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA.

Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme’s Cerezyme to Shire’s VPRIV, in the same dosage, several key health indicators remained the same.

For more information, please visit Shire.

FDA Approves Shire’s New Gaucher Drug 03/05/2010

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

MBBP client Shire Human Genetic Therapies, a global specialty biopharmaceutical company, announced last week that the U.S. Food and Drug Administration has approved their new drug VPRIV. VPRIV is a human cell line derived enzyme replacement therapy (ERT) meant to help treat Type 1 Gaucher disease. Shire’s drug has been prescribed to patients before its approval on an emergency basis for several months due to the shortage of Genzyme Corporation’s Cerezyme.

Shire Awarded $6.3 Million as Part of Tax Incentive Program 12/28/2009

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

Shire Human Genetic TherapiesThe Massachusetts Life Sciences Center has recently awarded 28 life sciences companies $25 million in tax incentives. MBBP client Shire Human Genetic Therapies Inc. was chosen as one of these companies, receiving $6,277,057. The Tax Incentive Program is directed at creating and keeping jobs in Massachusetts. The companies in the program have agreed to create 918 jobs in the next year and maintain them for at least 5 years.

Please visit the MLSC for more information on the Tax Incentive Program.

Follow

Get every new post delivered to your Inbox.

Join 51 other followers

%d bloggers like this: